Application Note: Evaluating the specificity and potency of PD-1 and PD-L1 blocking antibodies using AlphaLISA human and mouse PD-1/PD-L1 binding kits
Cancer immunotherapy utilises components of the immune system to treat cancer patients. These therapies are designed to work with a patient’s immune system to increase native anti-tumour responses. One type of immunotherapy relies on antibodies to bind to and inhibit the function of proteins expressed by the cancer cell…
To investigate and develop immunotherapies in mice, syngeneic models must be used instead of the xenograft models that lack a native immune system and often use human cell lines. Syngenic mouse models using tumour grafts derived from immortalised mouse cancer cell lines, enable the study of cancer therapies in the presence of an intact immune system. However, working in mouse systems can often require the development of separate mouse reagents, if the therapeutic agent of interest does not cross-react with a mouse.
In this application note we show how AlphaLISA® mouse PD-1/PD-L1 binding kit and AlphaLISA human PD-1/PD-L1 binding kit enable basic researchers and drug discovery researchers to develop and characterise anti-mouse or anti-human PD-1 and PD-L1 reagents for in vitro and in vivo studies, to test putative binding ligands (such as PD-L2) or characterise protein subregions for their ability to block the PD-1/PD-L1 binding interactions.
This application note is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Webinar highlights: Harmonising drug-target binding data analytics on a single platform
- Webinar preview: Compliance with data integrity and computerised system validations
- Harmonising drug-target binding data analytics on a single platform
- Compliance with data integrity and computerised system validations
- Assays In-Depth Focus 2018